Iron, HFE, and hemochromatosis update

Journal of Investigative Medicine

Volumn 45, Issue 9, 1997, Pages 518-529

  Cuthbert, Jennifer A ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HFE PROTEIN, HUMAN; HLA ANTIGEN; HLA ANTIGEN CLASS 1; IRON; MEMBRANE PROTEIN; PROTEIN;

ANIMAL; DISEASE MODEL; GENETICS; HEMOCHROMATOSIS; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; METABOLISM; PATHOLOGY; REVIEW;

ANIMALS; DISEASE MODELS, ANIMAL; HEMOCHROMATOSIS; HISTOCOMPATIBILITY ANTIGENS CLASS I; HLA ANTIGENS; HUMANS; IRON; MAJOR HISTOCOMPATIBILITY COMPLEX; MEMBRANE PROTEINS; PROTEINS;

EID: 0031296864     PISSN: 17088267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (119)

1. Simon M, Bourel M, Fauchet R, Genetet B. Association of HLA-A3 and HLA-B14 antigens with idiopathic haemochromatosis. Gut 1976;17:332-4.
2. Simon M, Bourel M, Genetet B, Fauchet R. Idiopathic hemochromatosis. Demonstration of recessive transmission and early detection by family HLA typing. N Engl J Med 1977;297:1017-21.
3. Feder JN, Gnirke A, Thomas W, Tsuchihashi Z, Ruddy DA, Basava A, Dormishian F, Domingo R Jr, Ellis MC, Fullan A, Hinton LM, Jones NL, Kimmel BE, Kronmal GS, Lauer P, Lee VK, Loeb DB, Mapa FA, McClelland E, Meyer NC. Mintier GA, Moeller N, Moore T, Morikang E, Prass CE, Quintana L, Starnes SM, Schatzman RC, Brunke KJ, Drayna DT, Risch NJ, Bacon BR, Wolff RR. A novel MHC class I-like gene is mutated in patients with hereditary haemochromatosis. Nat Genet 1996;13:399-408.
4. de Silva DM, Askwith CC, Kaplan J. Molecular mechanisms of iron uptake in eukaryotes. Physiol Rev 1996;76:31-47.
5. Britton RS, Bacon BR, Recknagel RO. Lipid peroxidation and associated hepatic organelle dysfunction in iron overload. Chem Phys Lipids 1987;45:207-39.
6. Bothwell TH. Overview and mechanisms of iron regulation. Nutr Rev 1995;53:237-45.
7. Gunshin H, Mackenzie B, Berger UV, Gunshin Y, Romero MF, Boron WF, Nussberger S, Gollan JL, Hediger MA. Cloning and characterization of a mammalian proton-coupled metal-ion transporter. Nature 1997;388:482-8.
8. Powell LW, Campbell CB, Wilson E. Intestinal mucosal uptake of iron and iron retention in idiopathic haemochromatosis as evidence for a mucosal abnormality. Gut 1970;11:727-31.
9. McLaren GD, Nathanson MH, Jacobs A, Trevett D, Thomson W. Regulation of intestinal iron absorption and mucosal iron kinetics in hereditary hemochromatosis. J Lab Clin Med 1991;117:390-401.
10. Pietrangelo A, Rocchi E, Casalgrandi G, Rigo G, Ferrari A, Perini M, Ventura E, Cairo G. Regulation of Transferrin, Transferrin Receptor, and Ferritin Genes in Human Duodenum. Gastroenterology 1992;102:802-9.
11. Qian ZM, Tang PL. Mechanisms of iron uptake by mammalian cells. Biochem Biophys Acta 1995;1269:205-14.
12. 125Ilabelled transferrin by rat liver. Biochem J 1986;237:163-73.
13. Osterloh K, Aisen P. Pathways in the binding and uptake of ferritin by hepatocytes. Biochim Biophys Acta 1989;1011:40-5.
14. Sciot R, Paterson AC, Van den Oord JJ, Desmet VJ. Lack of hepatic transferrin receptor expression in hemochromatosis. Hepatology 1987;7:831-7.
15. Lombard M, Bomford A, Hynes M, Naoumov NV, Roberts S, Crowe J, Williams R. Regulation of the hepatic transferrin receptor in hereditary hemochromatosis. Hepatology 1989;9:1-5.
16. Pietrangelo A, Rocchi E, Casalgrandi G, Rigo G, Ferrari A, Perini M, Ventura E, Cairo G. Regulation of transferrin, transferrin receptor, and ferritin genes in human duodenum. Gastroenterology 1992;102:802-9.
17. Girelli D, Olivieri O, De Franceschi L, Corrocher R, Bergamaschi G, Cazzola M. A linkage between hereditary hyperferritinaemia not related to iron overload and autosomal dominant congenital cataract. Br J Haematol 1995;90:931-4.
18. Girelli D, Corrocher R, Bisceglia L, Olivieri O, De Franceschi L, Zelante L, Gasparini P. Molecular basis for the recently described hereditary hyperferritinemiacataract syndrome: a mutation in the iron-responsive element of ferritin L-subunit gene (the "Verona mutation"). Blood 1995;86:4050-3.
19. Aguilar-Martinez P, Biron C, Masmejean C, Jeanjean P, Schved JF. A novel mutation in the iron responsive element of ferritin L-subunit gene as a cause for hereditary hyperferritinemia-cataract syndrome [letter]. Blood 1996;88:1895.
20. Hentze MW, Kuhn LC. Molecular control of vertebrate iron metabolism: mRNA-based regulatory circuits operated by iron, nitric oxide, and oxidative stress. Proc Natl Acad Sci USA 1996;93:8175-82.
21. Harrison PM, Arosio P. The ferritins: molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta 1996;1275:161-203.
22. Lipschitz DA, Cook JD, Finch CA. A clinical evaluation of serum ferritin as an index of iron stores. N Engl J Med 1974;290:1213-6.
23. Flanagan PR, Hajdu A, Adams PC. Iron-responsive element-binding protein in hemochromatosis liver and intestine. Hepatology 1995;22:828-32.
24. Jazwinska EC, Lee SC, Webb SI, Halliday JW, Powell LW. Localization of the hemochromatosis gene close to D6S105. Am J Hum Genet 1993;53:347-52.
25. Gasparini P, Borgato L, Pipemo A, Girelli D, Olivieri O, Gottardi E, Roetto A, Dianzani I, Fargion S, Schinaia G, et al. Linkage analysis of 6p21 polymorphic markers and the hereditary hemochromatosis: localization of the gene centromeric to HLA-F. Hum Mol Genet 1993;2:571-6.
26. Jazwinska EC, Pyper WR, Burt MJ, Francis JL, Goldwurm S, Webb SI, Lee SC, Halliday JW, Powell LW. Haplotype analysis in Australian hemochromatosis patients: evidence for a predominant ancestral haplotype exclusively associated with hemochromatosis. Am J Hum Genet 1995;56:428-33.
27. Raha-Chowdhury R, Bowen DJ, Stone C, Pointon JJ, Terwilliger JD, Shearman JD, Robson KJ, Bomford A, Worwood M. New polymorphic microsatellite markers place the haemochromatosis gene telomeric to D6S105. Hum Mol Genet 1995;4:1869-74.
28. Ajioka RS, Jorde LB, Gruen JR, Yu P, Dimitrova D, Barrow J, Radisky E, Edwards CQ, Griffen LM, Kushner JP. Haplotype analysis of hemochromatosis: evaluation of different linkage-disequilibrium approaches and evolution of disease chromosomes. Am J Hum Genet 1997;60:1439-47.
29. Burmeister WP, Gastinei LN, Simister NE, Blum ML, Bjorkman PJ. Crystal structure at 2.Å resolution of the MHC-related neonatal Fc receptor. Nature 1994;372:336-43.
30. Chorney MJ, Sawada I, Gillespie GA, Srivastava R, Pan J, Weissman SM. Transcription analysis, physical mapping, and molecular characterization of a nonclassical human leukocyte antigen class I gene. Mol Cell Biol 1990;10:243-53.
31. Shaheen NJ, Bacon BR, Grimm IS. Clinical characteristics of patients diagnosed with hereditary hemochromatosis who lack the Cys282Tyr mutation [abstract]. Gastroenterology 1997;112:A1381.
32. Beutler E, Gelbart T, West C, Lee P, Adams M, Blackstone R, Pockros P. Kosty M, Venditti CP. Phatak PD, Seese NK, Chorney KA, Tenelshof AE, Gerhard GS, Chorney M. Mutation analysis in hereditary hemochromatosis. Blood Cells Mol Dis 1996;22:187-94.
33. Jazwinska EC, Cullen LM, Busfield F, Pyper WR, Webb SI, Powell LW, Morris CP, Walsh TP. Haemochromatosis and HLA-H. Nat Genet 1996;14:249-51.
34. Jouanolle AM, Gandon G, Jezequel P, Blayau M, Campion ML, Yaouanq J, Mosser J, Fergelot P, Chauvel B, Bouric P, Cam G, Andrieux N, Gicquel I, Legall JY, David V. Haemochromatosis and HLA-H. Nat Genet 1996;14:251-2.
35. Carella M, D'Ambrosio L, Totaro A, Grifa A, Valentino MA, Piperno A, Girelli AR, Franco B, Gasparini P, Camaschella C. Mutation analysis of the HLA- H gene in Italian hemochromatosis patients. Am J Hum Genet 1997;60:828-32.
36. Merryweather-Clarke AT, Pointon JJ, Shearman JD. Robson, K. J. H. Global prevalence of putative hemochromatosis mutations 1997;34:275-8.
37. Roth MP, Giraldo P, Hariti G, Poloni ES, Sanchezmazas A, Destefano GF, Dugoujon JM, Coppin H. Absence of the hemochromatosis gene Cys282Tyr mutation in three ethnic groups from Algeria (MZAB), Ethiopia, and Senegal. Immunogenetics 1997;46:222-5.
38. Miyazaki J, Appella E, Ozato K. Intracellular transport blockade caused by disruption of the disulfide bridge in the third external domain of major histocompatibility complex class 1 antigen. Proc Natl Acad Sci U S A 1986;83: 757-61.
39. 2-microglobulin interaction and cell surface expression. J Biol Chem 1997;272:14025-8.
40. Parkkila S, Waheed A, Brittin RS, Feder JN, Tsuchihashi Z, Schatzman RC, Bacon BR, Sly WS. Immunohistochemistry of HLA-H, the protein defective in patients with hereditary hemochromatosis, reveals unique pattern of expression in gastrointestinal tract. Proc Natl Acad Sci U S A 1997;94:2534-9.
41. Simon M, Brissot P. The genetics of haemochromatosis. J Hepatol 1988;6:116-24.
42. Rotter JI, Diamond JM. What maintains the frequencies of human genetic diseases? Nature 1987 Sep 24-30;329:289-90.
43. Little P. Human genetics. Woman's meat, a man's poison. Nature 1996;382:494-5.
44. lancu TC. Animal models in liver research: iron overload. Adv Vet Sci Comp Med 1993;37:379-401.
45. 2-microglobulin-deficient mice. Immunol Lett 1994;39:105-11.
46. Rothenberg BE, Voland JR. 62 knockout mice develop parenchymal iron overload: A putative role for class I genes of the major histocompatibility complex in iron metabolism. Proc Natl Acad Sci USA 1996;93:1529-34.
47. Santos M, Schilham MW, Rademakers LHPM, Marx JJM, de Sousa M, Clevers H. Defective iron homeostasis in 62-microglobulin knockout mice recapitulates hereditary hemochromatosis in man. J Exp Med 1996;184:1975-85.
48. Bassett ML, Halliday JW, Powell LW. Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis. Hepatology 1986;6:24-9.
49. Adams PC, Deugnier Y, Moirand R, Brissot P. The relationship between iron overload, clinical symptoms and age in 410 patients with genetic hemochromatosis. Hepatology 1997;25:162-6.
50. Piperno A, Fargion S, D'Alba R, Roffi L, Fracanzani AL. Vecchi L, Failla M, Fiorelli G. Liver damage in Italian patients with hereditary hemochromatosis is highly influenced by hepatitis B and C virus infection. J Hepatol 1992;16:364-8.
51. Loreal O, Deugnier Y, Moirand R, Lauvin L, Guyader D, Jouanolle H, Turlin B, Lescoat G, Brissot P. Liver fibrosis in genetic hemochromatosis. Respective roles of iron and non-iron-related factors in 127 homozygous patients. J Hepatol 1992;16:122-7.
52. Summers KM, Halliday JW, Powell LW. Identification of homozygous hemochromatosis subjects by measurement of hepatic iron index. Hepatology 1990; 12:20-5.
53. Niederau C, Fischer R, Purschel A, Stremmel W, Haussinger D, Strohmeyer G. Long-term survival in patients with hereditary hemochromatosis. Gastroenterology 1996;110:1107-19.
54. Mandelli C, Cesarini L, Piperno A, Fargion S, Fracanzani AL, Barisani D, Conte D. Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology 1992;16:956-9.
55. LeSage GD, Baldus WP, Fairbanks VF, Baggenstoss AH, McCall JT, Moore SB, Taswell HF, Gordon H. Hemochromatosis: genetic or alcohol-induced? Gastroenterology 1983;84:1471-7.
56. Finch SC, Finch CA. Idiopathic hemochromatosis, an iron storage disease. A. Iron metabolism in hemochromatosis. Medicine 1955;34:381-430.
57. Liu P, Olivieri N. Iron overload cardiomyopathies: new insights into an old disease. Cardiovasc Drugs Ther 1994;8:101-10.
58. Jones AC, Chuck AJ, Arie EA, Green DJ, Doherty M. Diseases associated with calcium pyrophosphate deposition disease. Semin Arthritis Rheum 1992; 22:188-202.
59. Walton C, Kelly WF, Laing I, Bu'lock DE. Endocrine abnormalities in idiopathic haemochromatosis. Q J Med 1983;52:99-110.
60. Edwards CQ, Kelly TM, Ellwein G, Kushner JP. Thyroid disease in hemochromatosis. Increased incidence in homozygous men. Arch Intern Med 1983; 143:1890-3.
61. Kelly TM, Edwards CQ, Meikle AW, Kushner JP. Hypogonadism in hemochromatosis: reversal with iron depletion. Ann Intern Med 1984;101:629-32.
62. Siminoski K, D'Costa M, Walfish PG. Hypogonadotropic hypogonadism in idiopathic hemochromatosis: evidence for combined hypothalamic and pituitary involvement. J Endocrinol Invest 1990;13:849-53.
63. de Séze S, Solnica J, Mitrovic D, Miravet L, Dorfman H. Joint and bone disorders and hypoparathyroidism in hemochromatosis. Semin Arth Rheum 1972;2:71-94.
64. Hamilton EB, Bomford AB, Laws JW, Williams R. The natural history of arthritis in idiopathic haemochromatosis; progression of the clinical and radiological features over ten years. Q J Med 1981;50:321-9.
65. Elder GH, Roberts AG. Uroporphyrinogen decarboxylase. J Bioenerg Biomembr 1995;27:207-14.
66. Roberts AG, Whatley SD, Morgan RR, Worwood M, Elder GH. Increased frequency of the haemochromatosis Cys282Tyr mutation in sporadic poiphyria cutanea tarda. Lancet 1997;349:321-3.
67. Kushner JP, Edwards CQ, Dadone MM, Skolnick MH. Heterozygosity for HLA- linked hemochromatosis as a likely cause of the hepatic siderosis associated with sporadic porphyria cutanea tarda. Gastroenterology 1985;88:1232-8.
68. Dadone MM, Kushner JP, Edwards CQ, Bishop DT, Skolnick MH. Hereditary hemochromatosis. Analysis of laboratory expression of the disease by genotype in 18 pedigrees. Am J Clin Pathol 1982;78:196-207.
69. Bulaj ZJ, Griffin LM, Jorde LB, Edwards CQ, Kushner JP. Clinical and biochemical abnormalities in people heterozygous for hemochromatosis. N Engl J Med 1996;335:1799-805.
70. Bassett ML, Halliday JW, Ferns RA, Powell LW. Diagnosis of hemochromatosis in young subjects: predictive accuracy of biochemical screening tests. Gastroenterology 1984;87:628-33.
71. Beaumont C, Simon M, Fauchet R, Hespel JP, Brissot P, Genetet B, Bourel M. Serum ferritin as a possible marker of the hemochromatosis allele. N Engl J Med 1979;301:169-74.
72. Wands JR. Rowe JA, Mezey SE, Waterbury LA, Wright JR, Halliday JW, Isselbacher KJ, Powell LW. Normal serum ferritin concentrations in precirrhotic hemochromatosis. N Engl J Med 1976;294:302-5.
73. Herbert V, Jayatilleke E, Shaw S, Rosman AS, Giardina P, Grady RW, Bowman B, Gunter EW. Serum ferritin iron, a new test, measures human body iron stores unconfounded by inflammation. Stem Cells 1997;15:291-6.
74. Moirand R, Mortaji AM, Loréal O, Paillard F, Brissot P, Deugnier Y. A new syndrome of liver iron overload with normal transferrin saturation. Lancet 1997; 349:95-7.
75. Brink B, Disler P, Lynch S, Jacobs P, Charlton R, Bothwell T. Patterns of iron storage in dietary iron overload and idiopathic hemochromatosis. J Lab Clin Med 1976;88:725-31.
76. Blitzer BL, Weiss GB, Osbaldiston GW, Markham RB, Aamodt R. Berk PD, Wolff SM, Fauci AS. Early idiopathic hemochromatosis with absent stainable bone marrow iron stores. Gastroenterology 1978;75:886-8.
77. Sallie RW, Reed WD. Shilkin KB. Confirmation of the efficacy of hepatic tissue iron index in differentiating genetic haemochromatosis from alcoholic liver disease complicated by alcoholic haemosiderosis. Gut 1991;32:207-10.
78. Powell LW, Summers KM, Board PG, Axelsen E, Webb S, Halliday JW. Expression of hemochromatosis in homozygous subjects. Implications for early diagnosis and prevention. Gastroenterology 1990;98:1625-32.
79. Mandelli C. Cesarini L. Piperno A, Fargion S, Fracanzani AL, Bansani D. Conte D. Saturability of hepatic iron deposits in genetic hemochromatosis. Hepatology 1992;16:956-9.
80. Ludwig J, Hashimoto E, Porayko MK, Moyer TP, Baldus WP. Hemosiderosis in cirrhosis: a study of 447 native livers. Gastroenterology 1997;112:882-8.
81. Edwards CQ, Cartwright GE. Skolnick MH, Amos DB. Homozygosity for hemochromatosis: clinical manifestations. Ann Intern Med 1980;93:519-25.
82. Bernstein SE. Hereditary hypotransferrinemia with hemosiderosis, a murine disorder resembling human atransferrinemia. J Lab Clin Med 1987;110:690-705.
83. Yoshida K, Furihata K, Takeda S, Nakamura A, Yamamoto K, Morita H, Hiyamuta S, Ikeda S, Shimizu N, Yanagisawa N. A mutation in the ceruloplasmin gene is associated with systemic hemosiderosis in humans. Nat Genet 1995;9:267-72.
84. Harris ZL, Takahashi Y, Miyajima H, Serizawa M, MacGillvray RTA, Gitlin JD. Aceruloplasminemia: Molecular characterization of this disorder of iron metabolism. Proc Natl Acad Sci U S A 1995;92:2539-43.
85. Gordeuk V. Mukiibi J, Hasstedt SJ, Samowitz W, Edwards CQ, West G. Ndambire S, Emmanual J, Nkanza N, Chapanduka Z, Randall M, Boone P, Romano P. Martell RW, Yamashita T, Effler P, Brittenham G. Iron overload in Africa: Interaction between a gene and dietary iron content. N Engl J Med 1992;326:95-100.
86. Eason RJ, Aston CE, Adams PC, Searle J. Familial iron overload with possible autosomal dominant inheritance. Aust NZ J Med 1990;20:226-30.
87. Bonkovsky HL, Banner BF. Lambrecht RW, Rubin RB. Iron in liver diseases other than hemochromatosis. Semin Liver Dis 1996;16:65-82.
88. Wurapa RK, Gordeuk VR, Brittenham GM, Khiyami A, Schechter GP, Edwards CQ. Primary iron overload in African Americans. Am J Med 1996;101:9- 18.
89. Perkins KW, McInnes IWS, Blackburn CRB, Beal RW. Idiopathic haemochromatosis in children. Report of a family. Am J Med 1965;39:118-26.
90. Charlton RW, Abrahams C, Bothwell TH. Idiopathic hemochromatosis in young subjects. Clinical, pathological, and chemical findings in four patients. Arch Pathol 1967;83:132-40.
91. Menahem S, Salmon AP, Dennett X. Haemochromatosis presenting as severe cardiac failure in a young adolescent. Int J Cardiol 1990;29:86-9.
92. Haddy TB. Castro OL, Rana SR. Hereditary hemochromatosis in children, adolescents, and young adults. Am J Pediatr Hematol Oncol 1988;10:23-34.
93. Adams PC, Kertesz AE, Valberg LS. Rate of iron reaccumulation following iron depletion in hereditary hemochromatosis. Implications for venesection therapy. J Clin Gastroenterol 1993;16:207-10.
94. Agroyannis B, Koutsicos D, Tzanatou-Exarchou H, Varsou-Papadimitriou E, Kapetanaki A, Yatzidis H. Combined recombinant human erythropoietin-blood letting strategy for treating anemia and iron overload in hemodialysis patients. Int J Artif Organs 1991;14:403-6.
95. Fracanzani AL, Fargion S, Romano R, Conte D, Piperno A, D'Alba R, Mandelli C, Fraquelli M, Pacchetti S, Braga M, Fiorelli G. Portal hypertension and iron depletion in patients with genetic hemochromatosis. Hepatology 1995;22:1127-31.
96. Candell-Riera J, Lu L, Seres L, Gonzalez JB, Batlle J, Permanyer-Miralda G, Garcia-del-Castillo H, Soler-Soler J. Cardiac hemochromatosis: beneficial effects of iron removal therapy. An echocardiographic study Am J Cardiol 1983; 52:824-9.
97. Dabestani A, Child JS, Henze E. Perloff JK, Schon H, Figueroa WG, Schelbert HR, Thessomboon S. Primary hemochromatosis: anatomic and physiologic characteristics of the cardiac ventricles and their response to phlebotomy. Am J Cardiol 1984;54:153-9.
98. Cundy T, Butler J, Bomford A, Williams R. Reversibility of hypogonadotrophic hypogonadism associated with genetic haemochromatosis. Clin Endocrinol (Oxf) 1993;38:617-20.
99. Crawford DH, Halliday JW, Summers KM, Bourke MJ, Powell LW. Concordance of iron storage in siblings with genetic hemochromatosis: evidence for a predominantly genetic effect on iron storage. Hepatology 1993;17:833-7.
100. Askari AD, Muir WA, Rosner IA, Moskowitz RW, McLaren GD, Braun WE. Arthritis of hemochromatosis. Clinical spectrum, relation to histocompatibility antigens, and effectiveness of early phlebotomy. Am J Med 1983;75:957-65.
101. Sempos CT, Looker AC, Gillum RF, Makuc DM. Body iron stores and the risk of coronary heart disease. N Engl J Med 1994;330:1119-24.
102. Ammann RW, Muller E, Bansky J, Schuler G, Hacki WH. High incidence of extrahepatic carcinomas in idiopathic hemochromatosis. Scand J Gastroenterol 1980;15:733-6.
103. Hsing AW, McLaughlin JK, Olsen JH. Mellemkjar L, Wacholder S, Fraumeni Jr. JF. Cancer risk following primary hemochromatosis: a population-based cohort study in Denmark. Int J Cancer 1995;60:160-2.
104. Stevens RG, Jones DY, Micozzi MS, Taylor PR. Body iron stores and the risk of cancer. N Engl J Med 1988;319:1047-52.
105. Herrinton LJ, Friedman GD, Baer D, Selby JV. Transferrin saturation and risk of cancer. Am J Epidemiol 1995;142:692-8.
106. Kilpe VE, Krakauer H, Wren H. E. An analysis of liver transplant experience from 37 transplant centers as reported to Medicare. Transplantation 1993;56:554-61.
107. Grace ND. Liver transplantation for hemochromatosis: an ironic dilemma. Liver Transplant Surg 1995;1:234-6.
108. Kowdley KV, Hassanien T, Kaur S, Farrell FJ, Van Theil DH, Keefe EB, Sorrell MF, Bacon B. R., Webber FL Jr, Tavill AS. Primary liver cancer and survival in patients undergoing transplantation for hemochromatosis. Liver Transplant Surg 1995;1:237-41.
109. Pillay P, Tzoracoleftherakis E, Tzakis AG, Kakizoe S, Van Thiel DH, Starzl TE. Orthotopic liver transplantation for hemochromatosis. Transplant Proc 1991; 23:1888-9.
110. Adams PC, Ghent CN, Grant DR, Frei JV, Wall WJ. Transplantation of a donor liver with haemochromatosis: evidence against an inherited intrahepatic defect. Gut 1991;32:1082-3.
111. Dabkowski PL, Angus PW, Smallwood RA, Ireton J, Jones RM. Site of principal metabolic defect in idiopathic haemochromatosis: insights from transplantation of an affected organ. Br Med J 1993;306:1726.
112. Koskinas J, Portmann B, Lombard M, Smith T, Williams R. Persistent iron overload 4 years after inadvertent transplantation of a haemochromatotic liver in a patient with primary biliary cirrhosis. J Hepatol 1992;16:351-4.
113. Farrell FJ, Nguyen M, Woodley S, Imperial JC, Garcia-Kennedy R, Man K, Esquivel CO, Keeffe EB. Outcome of liver transplantation in patients with hemochromatosis. Hepatology 1994;20:404-10.
114. Olivieri NF, Brittenham GM. Iron-chelating therapy and the treatment of thalassemia. Blood 1997;89:739-61.
115. Schafer AI, Cheron RG, Dluhy R, Cooper B, Gleason RE, Soeldner JS, Bunn HF. Clinical consequences of acquired transfusional iron overload in adults. N Engl J Med 1981;304:319-24.
116. Phatak PD, Guzman G, Woll JE, Robeson A, Phelps CE. Cost-effectiveness of screening for hereditary hemochromatosis. Arch Intern Med 1994;154:769-76.
117. Buffone GJ, Beck JR. Cost-effectiveness analysts for evaluation of screening programs: hereditary hemochromatosis. Clin Chem 1994;40:1631-6.
118. Adams PC, Gregor JC, Kertesz AE, Valberg LS. Screening blood donors for hereditary hemochromatosis: decision analysis model based on a 30-year database. Gastroenterology 1995;109:177-88.
119. Baer DM, Simons JL, Staples RL, Rumore GJ, Morton CJ. Hemochromatosis screening in asymptomatic ambulatory men 30 years of age and older. Am J Med 1995;98:464-8.